|
1
|
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
|
Int J Obes (Lond)
|
2011
|
2.08
|
|
2
|
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.
|
Diabetes Obes Metab
|
2010
|
1.57
|
|
3
|
Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.
|
Curr Med Res Opin
|
2010
|
1.56
|
|
4
|
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.
|
Diabetes Res Clin Pract
|
2008
|
1.55
|
|
5
|
Vasopressin-dependent flank marking in golden hamsters is suppressed by drugs used in the treatment of obsessive-compulsive disorder.
|
BMC Neurosci
|
2001
|
0.77
|